Market Intelligence, Clinical Progress, and High-Purity Reagents for Thrombotic and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PF4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PF4 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View PF4 Products |
| Gene Delivery | PF4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PF4 Products |
| Benchmark Ab | Anti-PF4 Recombinant Antibody Recombinant positive control matching clinical/diagnostic benchmarks. |
View PF4 Products |
| Validator | PF4 siRNA Set For knockdown verification in functional assays. |
View PF4 Products |
| Related Target A | CXCR3 Primary G-protein coupled receptor mediating PF4/CXCL4 angiostatic and inflammatory signaling. |
View CXCR3 Products |
| Related Target B | CXCL10 Synergistic CXC chemokine sharing the CXCR3 receptor pathway in inflammatory cascades. |
View CXCL10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Oligomerization (Tetramerization) | HEK293 expressed recombinant PF4 ensures native folding and correct quaternary assembly. |
| Heparin-Induced Neoepitope Exposure | High-purity, endotoxin-controlled PF4 proteins strictly verified by mass spectrometry for consistent complex formation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PF4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PF4 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to targeted neutralizing monoclonal antibodies and small molecule inhibitors. As first-generation therapies for heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombotic thrombocytopenia (VITT) reach the clinic, the next wave of R&D is targeting PF4-mediated fibrosis, systemic sclerosis, and tumor microenvironment modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Academic Consortia, Biotech Startups | HIT, VITT, Thrombotic Disorders | Epitope mapping & heparin-complex binding assay (Need high-purity HEK293 PF4) |
| Small Molecule Antagonists | Pharmaceutical Developers | Systemic Sclerosis, Fibrosis | CXCR3 receptor binding inhibition (Need Lentivirus for stable cell line expression) |
| Diagnostic Biosimilars | In Vitro Diagnostic (IVD) Manufacturers | HIT/VITT Diagnostic Kits | Consistent antigen coating and benchmark antibody controls (Need Sequence Verified PF4) |